Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.


|Includes: Amarin Corporation PLC (AMRN)

Amarin was given notice of allowance for a very important patent - 669 that protects the Anchor population against other Rx. It also would provide legal protection, should Amarin want it against OTC products. This determination comes far earlier than expected and without further back and forth with USPTO. The bottom line is that no formula containing more than 4% DHA can participate in Anchor - meaning no other Rx, including Epanova. Amarin will be the only one to address the market, and the patent goes out beyond the current 2030 date on AMRN's other IP.

Because Anchor approval is around the corner, I am increasing my price target to $35, BD talks and BO should conclude before or shortly after FDA approval of Anchor.